Sartorius Stedim Biotech (SDMHF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech conference call and live webcast on H1-2026. I'm Moritz, your chorus call operator. I would like to remind you that all participants will be in a listen-only mode and the conference is being recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Petra Muller, Head of Investor Relations of Sartorius. Please go ahead. Thank you, and hello, and a warm welcome from my side. So today, I'm joined by our CEO, Michael Große, by Florian Funk, our CFO, by Rene Faber, Head of our Bioprocessing Division and CEO of Sotorius Stedim Biotech, and also by Alexandra Gatzemeier, Head of our Lab Products and Services Division. As always, we will start with prepared remarks followed by the Q&A session. The call is scheduled to last one hour. As usual, please limit your questions to one so that as many of you as possible can take part. In case we have some time at the end, we are, of course, happy to take on follow-on questions. I'd like to point out that management comments during this call will include forward-looking statements that involve risks and uncertainties. For discussion of risk factors, I encourage you to review the safe harbor statement contained in today's press release and the presentation. And with that, I'm pleased to hand over to our CEO, Michael Klose. Michael, please go ahead. Thank you, Petra. And a very warm welcome from my side as well. When I look back at the first half year, I'd say it's been an encouraging six months for ...